COMMUNIQUÉS West-GlobeNewswire

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
08/05/2025
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential [...]
OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
08/05/2025
OrganOx to benefit from Intuitive Ventures’ and Terumo Ventures’ unique operating and clinical experience OXFORD, England and MADISON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical [...]
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
08/05/2025
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons [...]
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
08/05/2025
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
08/05/2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Cassava Reports Q1 2025 Financials Results, Provides Business Update
08/05/2025
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 [...]
RAPT Therapeutics Reports First Quarter 2025 Financial Results
08/05/2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, [...]
Merus to Present at BofA Securities 2025 Health Care Conference
08/05/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics [...]
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
08/05/2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its [...]
Stryker declares an $0.84 per share quarterly dividend
08/05/2025
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the [...]
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
08/05/2025
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
08/05/2025
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and [...]
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
08/05/2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer [...]
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
08/05/2025
IND clearance and initiation of global basket trial exploring AlloNK ® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore [...]
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
08/05/2025
Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder [...]
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG- [...]
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
08/05/2025
COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains [...]
Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
08/05/2025
May 8, 2025 Announcement no. 15 Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first [...]
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
08/05/2025
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute [...]

Pages